{"filings":[{"id":2078916,"accession_number":"0001517022-26-000050","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2026-08-05T20:09:28+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akebia Q2 2026: Vafseo revenue $21.3M (+34% QoQ); net loss $8.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Vafseo net product revenue $21.3M in Q2 2026, up 34% from Q1; over 10,500 patients on therapy.","Total revenue $49.1M, down 20% YoY due to Auryxia generic competition ($25.5M vs $47.2M).","Net loss of $8.9M vs net income of $0.2M in Q2 2025; includes $1.9M restructuring charge.","Cash $155.5M as of June 30; company expects to fund operations for at least two years.","Initiated Phase 2 basket trial of ebribafusp for rare kidney diseases; initial data expected 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1342919,"accession_number":"0001517022-26-000047","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2026-06-30T12:05:11+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"VOICE trial interim analysis shows Vafseo superior to ESA on composite endpoint; trial stopped","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Win odds 1.16 (95% CI 1.06-1.28, p=0.0016) for all-cause mortality/hospitalization composite.","Hospitalizations per patient-year: 1.11 (Vafseo) vs 1.23 (ESA); incidence rate ratio 0.90 (p<0.05).","Mortality rates similar: 8.77% vs 8.78% per 100 patient-years; rate ratio 1.00 (CI 0.718-1.391).","Trial stopped on recommendation of Independent Data Monitoring Committee and Trial Steering Committee.","Results replicate safety findings from INNO2VATE phase 3 program; data to be submitted for scientific meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1195237,"accession_number":"0001517022-26-000043","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2026-06-22T20:16:44+00:00","items":["5.07"],"status":"ready","headline":"Akebia shareholders approve increase in authorized shares from 375M to 525M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 350M to 500M shares; total authorized capital from 375M to 525M.","Directors Adrian Adams, Michael Rogers, LeAnne Zumwalt elected as Class III for terms ending 2029.","Non-binding say-on-pay approved with 89.8M for vs 51.1M against; frequency vote favored annual (112.9M votes).","Ratification of Ernst & Young as auditor for FY2026 passed with 173.3M for vs 15.8M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93338,"accession_number":"0001517022-26-000038","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akebia posts Q1 net loss of $9.1M; Vafseo revenue rises to $15.8M, patients up 60%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.1M in Q1 2026 vs net income of $6.1M in Q1 2025; total revenues $53.5M, down from $57.3M.","Vafseo net product revenue $15.8M (+31% YoY); patients on Vafseo increased 60% vs Q4 2025; prescribers up 28%.","Auryxia net revenue $36.2M, down from $43.8M, with generic competition expected to expand in 2026.","Cash $162.6M at March 31, 2026; company expects sufficient cash to fund operations for at least two years.","Pipeline: praliciguat Phase 2 FSGS enrolling; AKB-097 basket study planned H2 2026; AKB-9090 Phase 1 initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":53544000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93337,"accession_number":"0001517022-26-000024","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Akebia appoints Philip Vickers to board, replacing retiring Steven Gilman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Gilman resigned as Class I director effective April 1, 2026; retirement not due to any disagreement.","Philip Vickers elected Class I director effective April 1, 2026; term expires at 2027 annual meeting.","Vickers appointed to Compensation and R&D Committees; receives standard non-employee director compensation.","Vickers granted 214,400 options at $1.41/share on April 1, plus annual cash retainers of $50,000.","Vickers is CEO of Solu Therapeutics; over 30 years biopharma leadership including Shire and Pfizer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104883,"accession_number":"0001517022-26-000019","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akebia Q4 net product revenue $54.3M, full-year 2025 up 49% YoY; Vafseo launch gains traction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $57.6M (FY2025 $236.2M); net loss narrowed to $12.2M Q4 and $5.3M full year.","Vafseo net product revenue $6.2M Q4, $45.8M full year 2025; 800 prescribers, 91% adherence with observed dosing.","Auryxia net rev $181.5M FY2025; generic competition expected to reduce 2026 Auryxia revenue.","Cash $184.8M vs $51.9M year-end 2024; sufficient for at least two years.","Pipeline: praliciguat Phase 2 FSGS started; AKB-097 basket study in 2H 2026; AKB-9090 Phase 1 in 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":236196000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104882,"accession_number":"0001517022-26-000008","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","2.03","5.02","9.01"],"status":"ready","headline":"Akebia leases 43,474 sq ft in Waltham for HQ; amends CEO/CFO severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leases 28,518 sq ft office + 14,956 sq ft lab at 180 Third Ave, Waltham, MA; HQ relocation planned for Sept 2026.","Annual office rent starts at $898,317, lab rent at $1,046,920; initial 84-month term with 5-year renewal option.","Security deposit of $810,515 in irrevocable letter of credit; landlord pays all work costs.","CEO John Butler severance: 12 months salary (non-CIC) or 24 months salary + 200% bonus (CIC); full equity vest on CIC.","CFO Erik Ostrowski severance: 12 months salary (non-CIC) or 12 months salary + 100% bonus (CIC); full vest of pre-2026 grants on CIC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104881,"accession_number":"0001517022-26-000003","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Akebia expects Q4 2025 Vafseo net revenue $5-6M; dosed first patient in praliciguat Phase 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vafseo Q4 net product revenue expected $5-6M (vs. underlying dosing demand $10.5-11.5M) due to $4.5-5M inventory adjustment at USRC.","Total Q4 prescribers ~785 (+8% QoQ); at least 25% of new patients from non-USRC centers (up from <10% Q3).","First patient dosed in praliciguat Phase 2 trial for FSGS; AKB-097 basket study starts H2 2026.","VOICE Phase IV fully enrolled (2,100+ patients); topline early 2027; VOCAL trial data expected Q4 2026.","Revenue growth expected to resume Q1 2026; broad prescribing access to ~275,000 dialysis patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121142,"accession_number":"0001517022-25-000051","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Akebia buys ADX-097 from Q32 Bio for $10M upfront (total up to $582M milestones); plans Phase 2 trials in 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront $7M paid at closing, additional $3M due in 6 months; development milestones up to $94.5M and commercial milestones up to $487.5M, plus tiered royalties from low single to mid-teen %.","AKB-097 is a tissue-targeted C3d-Factor H fusion protein complement inhibitor; Phase 2 basket trial in multiple rare kidney diseases planned to start treating subjects in 2026.","Praliciguat (sGC stimulator) Phase 2 trial initiated in FSGS; additional rare podocytopathy indications planned.","Existing cash resources plus cash from operations expected to fund current operating plan for at least 2 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121141,"accession_number":"0001517022-25-000048","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Akebia amends Medice license to supply vadadustat and grant manufacturing rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment #1 to License Agreement signed Nov 12, 2025 with MEDICE Arzneimittel Putter GmbH & Co. KG.","Akebia agrees to supply vadadustat drug substance under a concurrent supply agreement.","Medice granted right to manufacture Vafseo tablets using supplied drug substance.","Any know-how or patent rights from Medice's manufacturing owned by Akebia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121140,"accession_number":"0001517022-25-000045","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akebia Q3 net income $0.5M; Vafseo revenue $14.3M; DaVita pilot ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $58.8M (up 57% YoY vs $37.4M); net income $0.5M vs net loss $20.0M in Q3 2024.","Vafseo net product revenue $14.3M (launched Jan 2025); Auryxia net revenue $42.5M (up from $35.6M).","DaVita operational pilot started Aug 18 over 100 clinics, expected to complete in Q4; target 275K patient access by year-end.","FDA Type C meeting: no alignment on Phase 3 for non-dialysis; Akebia will not pursue broad label for non-dialysis.","Cash $166.4M; company believes financed to achieve profitability under current operating plan."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":178574000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121139,"accession_number":"0001517022-25-000040","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Akebia abandons Vafseo broad label pursuit for non-dialysis CKD after FDA alignment failure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Akebia will not initiate the VALOR trial for vadadustat in late-stage CKD not on dialysis after FDA feedback.","FDA indicated the trial would require significantly more patients and meaningfully more time and cost.","Akebia does not expect to pursue a broad label for Vafseo for non-dialysis dependent CKD patients.","Vafseo remains approved only for anemia in dialysis-dependent CKD patients; launched in U.S. Jan 2025.","Akebia is encouraged by FDA discussion on smaller subgroups but no specific path forward yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137782,"accession_number":"0001517022-25-000034","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akebia Q2 2025 net income $0.2M vs loss; Vafseo rev $13.3M, DaVita pilot in 100+ clinics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $0.2M (vs net loss of $8.6M in Q2 2024); total revenue $62.5M, up 43%.","Vafseo net product revenue $13.3M; prescription demand grew ~55% QoQ; >725 prescribers.","DaVita begins operational pilot in August at 100+ clinics; DCI/IRC protocols by Sept.","Auryxia net revenue $47.2M, up from $41.2M; no ANDA approved despite LOE in March.","Cash $137.3M; company believes financed to profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":119808000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155169,"accession_number":"0001517022-25-000030","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Akebia shareholders approve 18.9M share increase to 2023 Stock Incentive Plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved amendment to 2023 Stock Incentive Plan to increase shares by 18,900,000 (102.75M for, 48.21M against).","Directors John P. Butler and Myles Wolf re-elected as Class II directors with over 119.9M votes each.","Advisory vote on executive compensation passed with 110.68M for, 39.01M against.","Ratification of Ernst & Young as auditor for 2025 passed with 178.59M for, 8.90M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155168,"accession_number":"0001517022-25-000027","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akebia posts Q1 2025 net income of $6.1M; Vafseo launch generates $12.0M in net product rev","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q1 2025 net product revenues $55.8M, up 80% YoY; Vafseo contributed $12.0M in first quarter of U.S. launch.","Net income of $6.1M in Q1 2025 versus net loss of $18.0M in Q1 2024; driven by Vafseo and Auryxia sales.","Auryxia net revenues $43.8M (up from $31.0M YoY); market exclusivity lost March 20, 2025 but no ANDA approved.","Cash and equivalents $113.4M as of March 31, 2025, up from $51.9M at Dec 31, 2024, after $50M public offering.","Plan to initiate Phase 3 VALOR trial for vadadustat in non-dialysis CKD patients in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":57336000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173688,"accession_number":"0001193125-25-059327","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Akebia prices 25M-share public offering at $2.00/share, expects $46.5M net proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of 25M shares at $2.00/share; gross proceeds $50M.","Net proceeds ~$46.5M (or ~$53.6M if underwriters' option exercised in full).","Underwriters granted 30-day option to purchase up to 3.75M additional shares.","Expected closing March 21, 2025; Leerink Partners and Piper Sandler lead.","Company states it is financed to achieve profitability under current operating plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173687,"accession_number":"0001517022-25-000017","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akebia Q4 net loss $22.8M; expects Vafseo Q1 2025 revenue ~$10-11M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues Q4 $46.5M, down 17% YoY; Auryxia net revenue $44.4M vs $53.2M.","Net loss Q4 $22.8M vs net income $0.6M; FY2024 net loss $69.4M vs $51.9M.","Vafseo launch: shipments began Jan 9; >500 prescribers through Feb; Q1 revenue guidance $10-11M.","Cash $51.9M at Dec 31; post-year-end raised $18.4M ATM + $9.3M BlackRock; funded ≥2 years.","Plan to initiate Phase 3 VALOR trial for vadadustat in non-dialysis CKD in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173686,"accession_number":"0001517022-25-000010","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["1.01","2.03","3.02"],"status":"ready","headline":"Akebia draws $9.3M net from extended loan tranche; issues warrant for 1.15M shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended Tranche C expiry from Dec 31, 2024 to Feb 3, 2025; interest accrues from Dec 31, 2024.","Drew $10M Tranche C on Feb 3, 2025; net proceeds of $9.3M after debt issuance costs and interest.","Issued warrant to Kreos Capital affiliate for 1,153,846 shares at $1.30 exercise, 8-year term.","Warrant not registered; relies on Section 4(a)(2) and Rule 506(b) exemption.","Loan facility total $55M; prior tranches of $37M and $8M already drawn."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173685,"accession_number":"0001517022-25-000004","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Akebia guides cash runway of at least two years, funding Vafseo launch and pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects existing cash and cash from ops to fund current plan for at least two years.","Funding supports U.S. Vafseo launch and planned pipeline advancement.","CEO John Butler presenting at 43rd Annual J.P. Morgan Healthcare Conference on Jan 16, 2025.","Cautionary language regarding potential need for additional funding if plan changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190650,"accession_number":"0001517022-24-000075","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akebia Q3 2024 net loss $20M; Vafseo launch on track for Jan 2025 with 60% dialysis patient coverage","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $37.4M in Q3 2024 vs $42.0M in Q3 2023, driven by Auryxia volume decline.","Net loss $20.0M in Q3 2024 vs $14.5M in Q3 2023, including $4.4M non-cash interest from Vifor settlement.","Cash and equivalents $34.0M as of Sep 30, 2024; company expects funding to cover operations including Vafseo launch for at least two years.","Vafseo commercial supply contracts cover over 300,000 patients (~60% of US dialysis patients); TDAPA reimbursement starts Jan 1, 2025.","U.S. market availability for Vafseo expected in January 2025; VOICE trial initiated with US Renal Care."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":113683000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190649,"accession_number":"0001517022-24-000070","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Akebia signs multi-year supply agreement with leading dialysis org for Vafseo access","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Contract with a leading kidney care provider serving >200,000 patients at thousands of U.S. dialysis centers.","Vafseo (vadadustat) expected to be available in the U.S. in January 2025.","CMS granted TDAPA reimbursement for Vafseo starting January 1, 2025, and issued a HCPCS billing code.","Vafseo received FDA approval in March 2024 for anemia due to CKD in adults on dialysis for at least 3 months.","Agreement enables physicians to prescribe Vafseo as clinically appropriate; commercial launch priority."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190648,"accession_number":"0001517022-24-000067","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Akebia extends vadadustat supply agreement with STA through 2032","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment #1 to Supply Agreement with STA extended term to January 1, 2032.","Volume-based pricing structure and other provisions related to vadadustat drug product amended.","Original Supply Agreement entered February 10, 2021 for manufacturing of vadadustat."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207143,"accession_number":"0001517022-24-000065","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akebia Q2 2024 net loss narrows to $8.6M; Vafseo launch on track for Jan 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $43.6M (down 23% YoY); Auryxia net product rev $41.2M vs $42.2M in Q2 2023.","Net loss $8.6M vs $11.2M in Q2 2023; cash and equivalents $39.5M as of June 30, 2024.","Vafseo TDAPA application submitted; HCPCS codes expected Oct 2024, TDAPA by Jan 2025.","Set Vafseo WAC at $1,278 for 30-day supply (~$15,500/year); regained full U.S. rights from CSL Vifor.","Auryxia FY 2024 net product revenues expected in line with 2023 level ($167M in 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":76255000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207142,"accession_number":"0001517022-24-000061","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Akebia terminates Vafseo license with CSL Vifor, sets royalty payments and buy-down option","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License agreement terminated immediately for business reasons; Akebia regains full U.S. marketing rights for Vafseo.","Akebia to repay $40M working capital fund via quarterly tiered royalties of 8-14% of net sales through May 2028.","Settlement royalties: high single-digit % on net sales up to $450M, mid-single % above; buy-down option from July 2027.","Amended $55M Kreos loan facility to include covenants linked to the termination agreement.","Royalty payments commence July 1, 2025; minimum true-up milestones of $10M, $20M, $40M by 2026-2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224494,"accession_number":"0001517022-24-000059","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Akebia Therapeutics appoints Erik Ostrowski as CFO and Chief Business Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erik Ostrowski appointed Senior VP, CFO, Chief Business Officer and Treasurer, effective June 24, 2024.","Base salary of $540,000, annual bonus target up to 45% of base salary.","Granted options to purchase 500,000 shares (4-year vest) and 350,000 RSUs (3-year vest).","Ostrowski previously served as President/Interim CEO and CFO of AVROBIO, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224493,"accession_number":"0001517022-24-000057","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Akebia Therapeutics shareholders reject proposal to increase share reserve by 9.8M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three Class I directors elected: Ronald E. Frieson, Steven C. Gilman, Ph.D., Cynthia Smith.","Proposal to increase 2023 Stock Incentive Plan by 9.8M shares failed (52.8M against vs 45.2M for).","Advisory say-on-pay compensation approved narrowly (48.9M for, 47.4M against).","Ratification of Ernst & Young as independent auditor for FY 2024 approved (120.2M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224492,"accession_number":"0001517022-24-000050","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akebia Q1 net loss narrows to $18M; Vafseo FDA approved, launch set for Jan 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $32.6M (Q1 2024) vs $40.0M (Q1 2023); Auryxia net product revenues $31.0M vs $34.7M.","Net loss of $18.0M improved from $26.9M loss in prior year; R&D spend reduced to $9.7M from $19.7M.","Vafseo (vadadustat) FDA approved Mar 27 for dialysis anemia; launch activities underway, availability Jan 2025.","Drew $7.5M second tranche from BlackRock debt facility; $10M remaining borrowing capacity through Dec 31, 2024.","Amended Vifor license agreement: repayment of working capital fund via tiered royalties on Vafseo sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":32607000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224491,"accession_number":"0001517022-24-000035","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"Akebia draws $8.0M Tranche B from Kreos loan facility; $10.0M Tranche C still available","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Akebia drew $8.0M Tranche B loan on April 17, 2024, netting $7.5M after debt issuance costs and fees.","Remaining borrowing capacity under Tranche C is $10.0M, available through December 31, 2024.","Total facility remains $55M; initial $37M tranche was funded on January 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224490,"accession_number":"0001517022-24-000033","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Akebia extends vadadustat supply agreement with STA to 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment #2 extends Supply Agreement term to April 2, 2029 (five additional years).","Agreement covers manufacturing of vadadustat drug substance for commercial purposes.","Volume-based pricing structure was amended; no financial terms disclosed.","Original Supply Agreement dated April 2, 2020, previously amended April 15, 2021.","Contract manufacturer STA Pharmaceutical Hong Kong Limited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243805,"accession_number":"0001517022-24-000031","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Akebia Therapeutics receives FDA approval for Vafseo (vadadustat) for dialysis patients","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Vafseo for anemia due to CKD in adults on dialysis ≥3 months; boxed warning for thrombosis risks.","Vafseo is a once-daily oral HIF-PH inhibitor; already approved in 37 countries.","~500,000 U.S. adult dialysis patients suffer from CKD anemia.","Approval based on INNO2VATE Phase 3 program data published in NEJM 2021; plus Japan post-marketing data.","Akebia plans U.S. launch with commercial team and CSL Vifor partnership; conference call March 28."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243804,"accession_number":"0001193125-24-069123","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Akebia CFO Ellen Snow to depart March 22; CEO John Butler named interim principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Ellen Snow and company mutually agree on transition; effective March 22, 2024.","CEO John Butler will serve as interim principal financial officer starting Transition Date.","Separation agreement provides 12 months base salary, COBRA premium reimbursement, continued equity vesting.","Severance conditioned on general release of claims and compliance with non-compete and non-solicitation terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243803,"accession_number":"0001517022-24-000029","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akebia reports Q4 2023 net income $0.6M, Auryxia $53.2M; vadadustat PDUFA Mar 27","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $0.6M in Q4 2023 vs net loss $6.1M a year ago; full-year net income $51.9M vs loss $94.2M in 2022.","Auryxia net product revenue $53.2M in Q4, $170.3M full year, within guidance of $170-175M.","Vadadustat PDUFA date March 27, 2024; Akebia preparing for potential U.S. launch.","Closed $55M BlackRock term loan and raised $26M via ATM; cash $42.9M at year-end, sufficient for 24 months if vadadustat approved.","Appointed Nicholas Grund as Chief Commercial Officer; introduced early-stage pipeline programs AKB-9090 and AKB-10108."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243802,"accession_number":"0001517022-24-000019","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Akebia extends separation dates for COO Dahan to June 28 and CLO Hadas to June 14","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Michel Dahan's separation extended from March 22 to June 28, 2024.","SVP/Chief Legal Officer Nicole Hadas separation extended from March 29 to June 14, 2024.","Both amendments signed on February 8, 2024; earlier retention agreements dated May 5, 2022.","Separations may further extend to Sept 22, 2024 upon certain specified events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243801,"accession_number":"0001517022-24-000014","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["1.01","1.02","2.03","3.02"],"status":"ready","headline":"Akebia secures $55M Kreos term loan, draws $37M initial, issues warrants at $1.30, repays Pharmakon debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial draw of $37M under senior secured term loan; up to $55M total with two additional tranches contingent on vadadustat FDA approval and equity proceeds.","Warrant issued for 3,076,923 shares at $1.30 per share, exercisable for 8 years; additional warrant for 1,153,846 shares on Tranche C draw.","Interest rate at SOFR (floor 4.25%) + 6.75% margin (capped at 15%); interest-only period until Dec 2025 (extendable to Dec 2026).","Maturity extends to Jan 29, 2028 if vadadustat FDA approval obtained by June 30, 2024; otherwise maturity remains March 31, 2025 with accelerated amortization.","Proceeds used to repay in full the prior Pharmakon term loan and associated fees; loan secured by first-priority lien on substantially all assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243800,"accession_number":"0001517022-24-000007","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Akebia Therapeutics appoints Richard Malabre as Chief Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard C. Malabre named CAO effective January 8, 2024, reporting to CFO Ellen Snow.","Base salary of $380,000; annual cash bonus target up to 35% of base salary.","Granted options for 336,000 shares (4-year vest) and RSUs for 223,950 shares (3-year vest).","Malabre previously CFO of Ultivue, Inc. and VP/Corporate Controller at Oxford Immunotec.","Company will enter into standard Indemnification and Executive Severance Agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243799,"accession_number":"0001517022-24-000004","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Akebia discloses preliminary unaudited Auryxia net product revenue for FY2023 in JPM conference presentation","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation at 42nd Annual J.P. Morgan Healthcare Conference on Jan 11, 2024 includes preliminary Auryxia revenue.","Preliminary unaudited net product revenue for Auryxia for fiscal year ended Dec 31, 2023; exact figures not in filing text.","Investor and analyst meetings coincide with the J.P. Morgan Healthcare Conference starting Jan 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261206,"accession_number":"0001517022-23-000046","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Akebia extends manufacturing supply agreement with Siegfried through 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercised option to extend Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA.","Term extended from December 31, 2024 to December 31, 2026.","Extension notice provided on December 14, 2023; all other terms unchanged.","Supply continuity secured for active pharmaceutical ingredient manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261205,"accession_number":"0001517022-23-000044","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-11-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Akebia settles all patent disputes with FibroGen and Astellas in EU, UK, Japan","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement covers European (UK) Patent Nos. 2289531, 1463823, 2322155, 1633333, 2322153, 2298301 and Japanese Patent Nos. 4845728, 5474741, 5474872.","Resolves FibroGen's opposition to Akebia's European Patent No. 3357911 before the European Patent Office.","All ongoing litigation in UK courts and Japan Intellectual Property High Court to be terminated under agreement.","No financial terms or other business impact disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261204,"accession_number":"0001517022-23-000042","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akebia Q3 net loss $14.5M, Auryxia rev $40.1M, vadadustat PDUFA Mar 27, 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $14.5M from $54.1M in Q3 2022; total revenue $42.0M, down from $48.7M.","Auryxia net product revenue $40.1M (Q3 2022: $42.0M); FY 2023 guidance reaffirmed at $170-175M.","Vadadustat NDA resubmission accepted; PDUFA date set for March 27, 2024 for anemia in dialysis CKD.","Vadadustat approved in 36 countries including Australia and Taiwan; five posters at Kidney Week 2023.","Modified Pharmakon loan: principal payments deferred to Oct 2024, maturity extended to March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":138427000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261203,"accession_number":"0001517022-23-000040","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Akebia extends loan maturity to March 2025, removes SOFR cap","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity of $35M Term Loans from Nov 2024 to March 31, 2025.","Principal payments deferred until Oct 31, 2024, then monthly installments.","Removed 3.35% SOFR cap; interest now SOFR+0.3%+7.5% (~13.15% at amendment).","Prior capped rate was ~11.15%; removal increases borrowing cost."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261202,"accession_number":"0001517022-23-000037","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA accepts Akebia's resubmitted NDA for vadadustat; PDUFA date March 27, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resubmission classified as class 2 response; six-month review period from resubmission date.","Post-marketing safety data from tens of thousands of Japanese patients included in the filing.","Vadadustat currently approved in 35 countries; Akebia preparing for commercial launch in H2 2024 if approved.","PDUFA goal date of March 27, 2024; resubmission addressed issues from prior complete response letter.","CEO expects availability shortly after approval, offering an oral alternative for anemia in dialysis patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261201,"accession_number":"0001517022-23-000034","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Akebia extends Chief Legal Officer's departure date to March 29, 2024, with possible further extension","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Nicole R. Hadas, SVP, Chief Legal Officer and Corporate Secretary, will now separate on March 29, 2024 (previously October 6, 2023).","Under certain conditions, termination date may extend to September 22, 2024.","This is the fourth amendment to the original May 2022 retention and separation agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278469,"accession_number":"0001628280-23-033033","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Akebia: Vafseo approved in Australia; Auryxia 2023 revenue guidance lowered to $170-175M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Australia's TGA approved Vafseo (vadadustat) for anemia in dialysis patients; product now approved in 35 countries.","Akebia lowered Auryxia net product revenue guidance for 2023 to $170-175M from $175-180M due to market dynamics.","Company plans to resubmit U.S. NDA for vadadustat by end of Q3 2023.","Appointed Graham Ray (ex-Takeda) as VP, Key Accounts to lead U.S. launch prep and customer engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278468,"accession_number":"0001517022-23-000032","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akebia reports Q2 net loss $11.2M, plans vadadustat NDA resubmission by Q3 end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue Auryxia $42.2M (-2.5% YoY); reaffirms FY 2023 guidance $175-180M.","Total revenue $56.4M (down from $126.4M, largely due to Otsuka termination fee in prior year).","Cash $53.6M; expects to fund operations for at least 12 months.","Identified accounting errors on product returns; material weakness; will amend 2020-2022 financials.","Plan to resubmit vadadustat NDA by Sept 30, 2023; potential PDUFA March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":96381000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278467,"accession_number":"0001517022-23-000029","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-08-17T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Akebia receives Nasdaq deficiency notice for late Q2 filing; plans to file by Aug 25","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Form 10-Q for Q2 2023 not filed on time; Nasdaq gave non-compliance notice on Aug 11, 2023.","Accounting errors identified regarding return reserves for Auryxia in prior financial statements.","Company has 60 days to submit a plan; expects to file Form 10-Q by August 25, 2023.","Common stock continues trading on Nasdaq; Akebia expects to regain compliance upon filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278466,"accession_number":"0001517022-23-000027","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Akebia delays Form 10-Q filing due to accounting errors; reaffirms 2023 revenue guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Identified accounting errors in recording Auryxia return reserves, delaying Q2 2023 Form 10-Q filing.","Reaffirms 2023 Auryxia net product revenue guidance of $175-$180 million.","Cash as of June 30, 2023 plus Auryxia revenues expected to fund operations through at least next twelve months.","Expects to resubmit NDA for vadadustat for anemia due to CKD in dialysis patients by end of Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278465,"accession_number":"0001517022-23-000023","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Akebia extends COO Dahan and CLO Hadas separation dates to 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Michel Dahan termination extended to March 22, 2024 (could extend to Sept 22, 2024 under certain events).","Chief Legal Officer Nicole Hadas termination extended to Oct 6, 2023 (could extend to March 22, 2024).","Both changes are amendments to retention/separation agreements from Nov 2022 and May 2023.","Extensions are part of the workforce reduction announced May 9, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278464,"accession_number":"0001517022-23-000019","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Akebia completes FDA Type A meeting; expects to resubmit vadadustat NDA by Q3 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Completed End of Dispute Type A meeting with FDA to align on NDA resubmission for vadadustat for anemia due to CKD in dialysis patients.","Expects to receive FDA meeting minutes by mid-August 2023; resubmission planned by end of third quarter 2023.","Upon NDA acceptance, expects PDUFA date six months from submission; vadadustat is approved in 34 countries including recent Swissmedic approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296649,"accession_number":"0001517022-23-000017","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO David Spellman resigns; Ellen Snow appointed as new CFO effective July 17, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Spellman resigns as CFO, effective June 23, 2023; will receive 12 months base salary continuation and COBRA reimbursement.","Ellen Snow appointed SVP, CFO, Treasurer effective July 17, 2023; base salary $450k, bonus 45% target, equity grants (560k options, 370k RSUs).","CEO John Butler serves as interim principal financial officer from June 23 to July 17, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296648,"accession_number":"0001517022-23-000014","cik":1517022,"company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Akebia shareholders elect three directors, approve 2023 stock plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class III directors Adrian Adams, Michael Rogers, LeAnne M. Zumwalt elected for three-year terms.","2023 Stock Incentive Plan approved: 61.2M for, 22.8M against, 508K abstentions.","Non-binding advisory vote on executive compensation passed: 59.7M for, 24.2M against.","Ernst & Young LLP ratified as auditor for FY2023: 116.5M for, 5.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":278988561.3203883,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-08T23:59:59+00:00|296648"}